Single-center , double-blind , randomized , placebo-controlled , parallel-group study in 36 volunteers who received voriconazole ( n = 18 , 400 mg every 12 h on day 1 , then 300 mg every 12 h for 27.5 days ) or matched placebo ( n = 18 ) .